Sector: Health Care
Director information for ALNYLAM PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Amy W. Schulman | CHAIR OF THE BOARD | 65 | ["Managing partner at Polaris Partners","Former Executive Chair of Lyndra Therapeutics, Inc.","Former senior lecturer at Harvard Business School","Former Executive Vice President and General Counsel of Pfizer","Experience in commercial strategy, legal, regulatory, and transactional considerations"] | ["People, Culture and Compensation Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Colleen F. Reitan | Independent Director | 66 | ["Over 30 years of experience in the healthcare payor and reimbursement market","President of Plan Operations of HCSC","Chief Operating Officer of HCSC","President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota","Experience with provider network management, strategic planning and business development","Asset to audit committee and PC&C committee","audit committee financial expert"] | ["Audit Committee","People, Culture and Compensation Committee"] | 2026 |
| David E.I. Pyott | Independent Director; Chair | 72 | ["Chief Executive Officer of Allergan, Inc. from January 1998 to March 2015","Chair of Allergan’s board of directors from March 2001 until March 2015","Head of the Nutrition Division at Novartis AG","Member of the Executive Committee of Novartis AG","Director of Pliant Therapeutics, Inc. and Tarsus Pharmaceuticals","Director of BioMarin Pharmaceutical Inc.","Member of the Supervisory Board of Royal Philips NV","Over 30 years of operational, commercial and senior management experience","Extensive public company governance experience"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Dennis A. Ausiello, M.D. | Director; Member | 80 | ["Director of the Center for Assessment Technology and Continuous Health (CATCH)","Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School","Physician-in-Chief Emeritus at Massachusetts General Hospital","Former Chief of Medicine at Massachusetts General Hospital","Past President of the Association of American Physicians","Member of the National Academy of Medicine","Member of the American Academy of Arts and Sciences"] | ["Nominating and Corporate Governance Committee","Science and Technology Committee"] | 2026 |
| Elliott Sigal, M.D., Ph.D. | Director; Chair | 74 | ["Chief Scientific Officer of Bristol-Myers Squibb","Member of the BMS board of directors","Vice President of R&D and Chief Executive Officer for Mercator Genetics Inc.","Senior advisor to New Enterprise Associates","Co-chair of the Scientific Advisory Board for Amgen, Inc.","Director of Vir Biotechnology, Inc.","Former director of Adaptimmune Therapeutics plc","Former director of Surface Oncology Inc."] | ["People, Culture and Compensation Committee","Science and Technology Committee"] | 2026 |
| Margaret A. Hamburg, M.D. | Independent Director | 70 | ["Co-President of the InterAcademy Partnership","Former Commissioner of the U.S. Food and Drug Administration (FDA)","Interim Vice President, Global Biological Policy and Programs at the Nuclear Threat Initiative","Foreign Secretary of the National Academy of Medicine","Former President/Chair of the Board of the American Association for the Advancement of Science","Former Vice President for biological programs at the Nuclear Threat Initiative","Former Assistant Secretary for Planning and Evaluation in the Department of Health and Human Services","Former New York City’s health commissioner","Commissioner on the Bipartisan Commission on Biodefense","Board of Fellows at Harvard Medical School"] | ["Nominating and Corporate Governance Committee"] | 2026 |
| Olivier Brandicourt, M.D. | Independent Director | 70 | ["Senior Advisor at Blackstone since December 2019","Former Chief Executive Officer and board member of Sanofi","Former Chief Executive Officer and Chair of Bayer HealthCare AG","Former various operational and managerial positions at Pfizer","Director of BeOne Medicines Ltd. and Vaxcyte, Inc.","Over 30 years of global commercial experience in the biopharmaceutical industry"] | ["People, Culture and Compensation Committee","Audit Committee"] | 2026 |
| Peter N. Kellogg | Independent Director; Chair | 69 | ["Executive Vice President and Chief Corporate Strategy Officer of Celgene Corporation","Executive Vice President and Chief Financial Officer of Celgene","Chief Financial Officer and Executive Vice President of Merck & Co. Inc.","Executive Vice President, Finance and Chief Financial Officer at Biogen, Inc.","Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc.","Senior Vice President and Chief Financial Officer, Frito-Lay International","Previous director of Idorsia Ltd.","audit committee financial expert"] | ["Audit Committee"] | 2026 |
| Stuart A. Arbuckle | Director | 60 | ["more than 30 years of global commercial and leadership experience at leading biopharmaceutical companies","senior executive roles at Vertex and Amgen","extensive expertise in building and leading high-performing commercial organizations","driving successful product launches","scaling operations across diverse geographies","substantial public company governance experience"] | [] | 2026 |
| Yvonne L. Greenstreet, M.D. | Chief Executive Officer | 63 | ["CEO since January 2022","President and Chief Operating Officer from October 2020 to January 2022","Chief Operating Officer from September 2016 to October 2020","Founder and Managing Director of Highgate LLC","Senior Vice President and Head of Medicines Development at Pfizer Inc.","18 years at GlaxoSmithKline plc in various positions","Senior Vice President and Head of Medicines Development at Pfizer"] | ["Biotechnology Industry Organization Health Section Governing Board"] | 2026 |
